²é¿´: 1392  |  »Ø¸´: 14
µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû

lovelhw

½ð³æ (³õÈëÎÄ̳)

[ÇóÖú] ¹òÇó°ïÎÒ·­ÒëÒ»ÏÂÕâ¶ÎÎÄ×Ö£¬Ö°³ÆÂÛÎļ±ÐèÒª

Ä¿µÄ  ¹Û²ì°¢Íз¥ËûÍ¡ÁªºÏ°¢Ë¹Æ¥ÁÖÖÎÁÆÔ­·¢ÐÔ¸ßѪѹºÏ²¢¾±¶¯ÂöÖàÑùÓ²»¯°ß¿éµÄÁÆÐ§¡£·½·¨  ´æÔÚ¾±¶¯ÂöÖàÑùÓ²»¯°ß¿éµÄÔ­·¢ÐÔ¸ßѪѹ»¼Õß60Àý£¬Ëæ»ú·ÖΪ¶ÔÕÕ×é×é30Àý£¬¸øÓèµ¥Óð¢Ë¹Æ¥ÁÖÆ¬£¬ÖÎÁÆ×é30Àý£¬¸øÓè°¢Íз¥ËûÍ¡ÁªºÏ°¢Ë¹Æ¥ÁÖ£»ÖÎÁÆÇ°¼°ÖÎÁƺó1¡¢3¡¢6Ô²ⶨ»¼ÕßÈýõ£¸ÊÓÍ(TG)¡¢ÑªÇå×ܵ¨¹Ì´¼(CH)¡¢µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼(LDL¡ªC)¡¢ÈéËáÍÑÇâø(LDH)ºÍ¾±¶¯ÂöÄÚÖÐĤºñ¶È(IMT)¡¢°ß¿é»ý·ÖµÄ±ä»¯¡£½á¹û ÖÎÁÆ6¸öÔºóÈýõ£¸ÊÓÍ(TG)¡¢×ܵ¨¹Ì´¼(TC)¡¢ÑªÇå×ܵ¨¹Ì´¼(CH)¡¢µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼(LDL¡ªC)¡¢°ß¿é»ý·ÖºÍ¾±¶¯ÂöÄÚÖÐĤºñ¶È(IMT)¡¢·Ö±ðΪ(2.05ÍÁ0.9)mmol£¯L  ½áÂÛ °¢Íз¥ËûÍ¡ÁªºÏ°¢Ë¹Æ¥ÁÖ£¬¶ÔËõС¾±¶¯ÂöÖàÑù°ß¿éÌå»ý¡¢Îȶ¨°ß¿é¡¢½µµÍѪ֬¸÷ÏîÖ¸±êÓнϺõÄЧ¹û£¬¿É×÷Ϊԭ·¢ÐÔ¸ßѪѹºÏ²¢¾±¶¯ÂöÖàÑùÓ²»¯°ß¿éÖÎÁƵÄÁªºÏÒ©Îï¡£

» ²ÂÄãϲ»¶

ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lovelhw

½ð³æ (³õÈëÎÄ̳)

·Ö±ðΪ(2.05ÍÁ0.9)mmol£¯L¡¢(5.21Ê¿1.3)mmol£¯L¡¢(2.65¡À1.1)mmol£¯L¡¢(4.01Ê¿1.35)mmol£¯L¡¢(0.99Ê¿0.25)mm£¬µÍÓÚ¶ÔÕÕ×é[(2.59¡À1.2)mmol£¯L¡¢(6.30¡À2.0)mmol£¯L¡¢(3.20¡À1.2)mmol£¯L ¡¢(4.98¡À1.73)mmol£¯L¡¢(1.12¡À0.26)mm£¬(¾ùP<O£®05)¡£
7Â¥2013-10-27 23:32:11
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
²é¿´È«²¿ 15 ¸ö»Ø´ð

befair

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

ÄãºÃ£¬¿´Äã±È½Ï׿±£¬µ«ÒòΪ²»ÊÇÕâ¸öרҵµÄ£¬ÕâÀïµÄרҵ´Ê»ãÌ«¶à£¬·­ÆðÀ´ÄÑÒÔרҵ¡£Èç¹ûÄ㻹ÐèÒª°ïÖúµÄ»°£¬¿É·ñÏȸø³öרҵ´Ê»ã£¬´ó¼Ò¿ÉÒÔ°ïÖúÄã×éÖ¯Æð½á¹¹À´£¿
Befairorbeaware
2Â¥2013-10-25 20:19:03
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lovelhw

½ð³æ (³õÈëÎÄ̳)

°¢Íз¥ËûÍ¡Atorvastatin         °¢Ë¹Æ¥ÁÖAspirin         Ô­·¢ÐÔ¸ßѪѹprimary hypertension
¾±¶¯ÂöÖàÑùÓ²»¯°ß¿éCarotid atherosclerotic lesions            Èýõ£¸ÊÓÍtriglyceride   
ѪÇå×ܵ¨¹Ì´¼cholesteol    µÍÃܶÈÖ¬µ°°×µ¨¹Ì´¼low density lipoprotein-cholesterol
ÈéËáÍÑÇâølactate dehydrogenase            ¾±¶¯ÂöÄÚÖÐĤºñ¶ÈIntima-media thickness
°ß¿é»ý·Öcrouse score        ÑªÖ¬blood fat         ¸Ð¼¤¸÷λ´óÏÀ£¡£¡£¡
3Â¥2013-10-26 10:19:32
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

befair

Ìú¸Ëľ³æ (ÕýʽдÊÖ)

¡¾´ð°¸¡¿Ó¦Öú»ØÌû

¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ¡ï ...
°®ÓëÓêÏÂ: ½ð±Ò+1 2013-11-16 06:03:08
lovelhw(phu_grassman´ú·¢): ½ð±Ò+50, you're always so kind 2014-01-16 15:55:52
lovelhw(phu_grassman´ú·¢): ½ð±Ò+25, thanks 2014-01-16 15:56:02
Objectives: To observe effectiveness of using atorvastatin in combination with aspirin for primary hypertension complicated by carotid atherosclerotic lesions.
Methodology: The 60 patients of primary hypertension with carotid atherosclerotic lesions are randomly put into a control group of 30 patients who are prescribed  aspirin only, and a treatment group of 30 patients who are prescribed atorvastatin and aspirin. Prior to the treatment and one, three and six months after it,  the patients are tested for their TG, CH, LDL-C, LDH, IMT and crouse score, in particular the changes.
Results: Six months after the treatment, all the TG, TC, CH, LDL-C, IMT values are (2.05ÍÁ0.9)mmol£¯L
Conclusions: Atorvastatin in combination with aspirin is effective for reducing volume of carotid atherosclerotic lesions, stabalising the crouse and reducing blood fat as well as other indices. Hence it can be used as a drug combination for treatment of  primary hypertension with carotid atherosclerotic lesions.
½á¹ûÒ»¾ä£º Ô­ÎÄ˵ÄÇЩָ±ê¶¼·Ö±ðÊÇ (2.05ÍÁ0.9)mmol£¯L£¬ ÄÇô¾ÍÊÇ˵ËüÃǶ¼ÊÇ (2.05ÍÁ0.9)mmol£¯L£¿»¹ÊÇËüÃÇ·Ö±ðÊÇA£¬ B£¬ C,¡£¡£¡£ÇëÈ·ÈÏ
·Ç±¾×¨Òµ£¬½ö¹©²Î¿¼
Befairorbeaware
4Â¥2013-10-26 16:22:37
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
×î¾ßÈËÆøÈÈÌûÍÆ¼ö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[¿¼ÑÐ] ²ÄÁÏѧ˶301·ÖÇóµ÷¼Á +7 Liyouyumairs 2026-03-21 7/350 2026-03-21 22:31 by peike
[¿¼ÑÐ] ²ÄÁÏÇóµ÷¼Á +5 @taotao 2026-03-21 5/250 2026-03-21 20:55 by lbsjt
[¿¼ÑÐ] 0703»¯Ñ§µ÷¼Á +11 ÄÝÄÝninicgb 2026-03-15 15/750 2026-03-21 19:15 by ColorlessPI
[¿¼ÑÐ] 299Çóµ÷¼Á +5 shxchem 2026-03-20 7/350 2026-03-21 17:09 by ColorlessPI
[»ù½ðÉêÇë] ѧУÒѾ­Ìá½»µ½NSFC£¬»¹ÄÜÐÞ¸ÄÂ𣿠40+4 babangida 2026-03-19 9/450 2026-03-21 16:12 by babangida
[¿¼ÑÐ] 22 350 ±¾¿Æ985Çóµ÷¼Á£¬ÇóÀϵÇÊÕÁô +3 ÀîéóÄÐ003 2026-03-20 3/150 2026-03-21 13:28 by ²«»÷518
[¿¼ÑÐ] 306Çóµ÷¼Á +4 chuanzhu´¨Öò 2026-03-18 4/200 2026-03-21 08:25 by laoshidan
[¿¼ÑÐ] ³õʼ318·ÖÇóµ÷¼Á£¨Óй¤×÷¾­Ñ飩 +3 1911236844 2026-03-17 3/150 2026-03-21 02:33 by JourneyLucky
[¿¼ÑÐ] Ò»Ö¾Ô¸ÖйúʯÓÍ´óѧ£¨»ª¶«£© ±¾¿ÆÆë³¹¤Òµ´óѧ +3 ʯÄÜΰ 2026-03-17 3/150 2026-03-21 02:22 by JourneyLucky
[¿¼ÑÐ] 324·Ö 085600²ÄÁÏ»¯¹¤Çóµ÷¼Á +4 llllkkkhh 2026-03-18 4/200 2026-03-21 01:24 by JourneyLucky
[¿¼ÑÐ] 294Çóµ÷¼Á²ÄÁÏÓ뻯¹¤×¨Ë¶ +15 ݤÎÉ­ÁÖ 2026-03-18 15/750 2026-03-20 23:28 by JourneyLucky
[¿¼ÑÐ] 0817 »¯Ñ§¹¤³Ì 299·ÖÇóµ÷¼Á ÓпÆÑо­Àú ÓжþÇøÎÄÕ +22 rare12345 2026-03-18 22/1100 2026-03-20 20:39 by zhukairuo
[¿¼ÑÐ] Ò»Ö¾Ô¸»ªÖÐũҵ071010£¬×Ü·Ö320Çóµ÷¼Á +3 À§À§À§À§À¤À¤ 2026-03-20 3/150 2026-03-20 20:38 by ѧԱ8dgXkO
[¿¼ÑÐ] 085410È˹¤ÖÇÄÜר˶317Çóµ÷¼Á£¨0854¶¼¿ÉÒÔ£© +4 xbxudjdn 2026-03-18 4/200 2026-03-20 09:07 by ²»168
[¿¼ÑÐ] Çóµ÷¼Á +3 °µÓ¿afhb 2026-03-16 3/150 2026-03-20 00:28 by ºÓÄÏ´óѧУÓÑ
[ÂÛÎÄͶ¸å] ÉêÇë»Ø¸åÑÓÆÚÒ»¸öÔ£¬±à¼­Í¬ÒâÁË¡£µ«ÏµÍ³ÉϵÄʱ¼äû±ä£¬¸ø±à¼­ÓÖдÓʼþÁË£¬Ã»»Ø¸´ 10+3 wangf9518 2026-03-17 4/200 2026-03-19 23:55 by babero
[¿¼ÑÐ] ±¾¿ÆÖ£ÖÝ´óѧÎïÀíѧԺ£¬Ò»Ö¾Ô¸»ª¿Æ070200ѧ˶£¬346Çóµ÷¼Á +4 ÎÒ²»ÊÇÒ»¸ù´Ð 2026-03-18 4/200 2026-03-19 09:11 by ¸¡ÔÆ166
[¿¼ÑÐ] 0854£¬¼ÆËã»úÀàÕÐÊÕµ÷¼Á +3 ºúÀ±ÌÀ·ÅÌÇ 2026-03-15 6/300 2026-03-18 12:09 by Éϰ¶Éϰ¶¡­¡­..
[¿¼ÑÐ] 334Çóµ÷¼Á +3 Ö¾´æ¸ßÔ¶ÒâÔÚ»úÐ 2026-03-16 3/150 2026-03-18 08:34 by lm4875102
[¿¼ÑÐ] ÓÐûÓеÀÌú/ÍÁľµÄÏëµ÷¼ÁÄÏÁÖ£¬¸ø×Ô¼ºÕÐʦµÜÖС« +3 TqlXswl 2026-03-16 7/350 2026-03-17 15:23 by TqlXswl
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û